|
Orthologous residues
|
|
C/EBP‑alpha (human): S21‑p, C/EBP‑alpha (mouse): S21‑p, C/EBP‑alpha (rat): S21‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], adipose tissue, bone marrow, liver, lung
|
|
Cellular systems studied:
cell lines, tissue
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK1 (human)
|
pharmacological activator of upstream enzyme, mutation in upstream enzyme recognition motif, pharmacological inhibitor of upstream enzyme
|
|
|
KINASE
|
ERK2 (human)
|
pharmacological activator of upstream enzyme, mutation in upstream enzyme recognition motif, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
PDGF
|
|
|
|
increase
|
|
|
U0126
|
PD98059
|
|
|
inhibit treatment-induced increase
|
|
|
serum
|
|
|
|
increase
|
|
|
U0126
|
serum
|
|
|
inhibit treatment-induced increase
|
|
|
phorbol ester
|
|
|
|
increase
|
|
|
U0126
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
PD98059
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
insulin
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
inhibition, protein conformation
|
